StockNews.com lowered shares of Sabre (NASDAQ:SABR – Free Report) from a buy rating to a hold rating in a report published on Wednesday morning.
Sabre Trading Up 1.9 %
Shares of SABR opened at $3.69 on Wednesday. The company has a market cap of $1.42 billion, a PE ratio of -4.67 and a beta of 1.74. The stock has a 50-day moving average price of $3.43 and a 200-day moving average price of $3.13. Sabre has a 12-month low of $1.81 and a 12-month high of $4.68.
Sabre (NASDAQ:SABR – Get Free Report) last released its earnings results on Thursday, October 31st. The information technology services provider reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $764.71 million during the quarter, compared to the consensus estimate of $774.53 million. The business’s quarterly revenue was up 3.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.10) EPS. As a group, analysts predict that Sabre will post -0.3 earnings per share for the current year.
Institutional Trading of Sabre
About Sabre
Sabre Corporation, together with its subsidiaries, operates as software and technology company for travel industry in the United States, Europe, Asia-Pacific, and internationally. It operates through two segments: Travel Solutions and Hospitality Solutions. The Travel Solutions segment operates a business-to-business travel marketplace that offers travel content, such as inventory, prices, and availability from a range of travel suppliers, including airlines, hotels, car rental brands, rail carriers, cruise lines, and tour operators with a network of travel buyers comprising online and offline travel agencies, travel management companies, and corporate travel departments.
See Also
- Five stocks we like better than Sabre
- Are Penny Stocks a Good Fit for Your Portfolio?
- Can United States Cellular Ride Higher on Its Spectrum Strategy?
- ETF Screener: Uses and Step-by-Step Guide
- HubSpot’s Growth in CRM: Can It Compete With Salesforce?
- 5 discounted opportunities for dividend growth investors
- Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?”
Receive News & Ratings for Sabre Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sabre and related companies with MarketBeat.com's FREE daily email newsletter.